Stoke Therapeutics/$STOK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Stoke Therapeutics
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Ticker
$STOK
Sector
Primary listing
Employees
128
Headquarters
Website
STOK Metrics
BasicAdvanced
$1.7B
33.25
$0.91
1.15
-
Price and volume
Market cap
$1.7B
Beta
1.15
52-week high
$32.40
52-week low
$5.35
Average daily volume
1.1M
Financial strength
Current ratio
6.98
Quick ratio
6.446
Long term debt to equity
0.375
Total debt to equity
0.375
Interest coverage (TTM)
13,427.33%
Profitability
EBITDA (TTM)
42.271
Gross margin (TTM)
100.00%
Net profit margin (TTM)
26.26%
Operating margin (TTM)
20.15%
Effective tax rate (TTM)
2.38%
Revenue per employee (TTM)
$1,560,000
Management effectiveness
Return on assets (TTM)
7.27%
Return on equity (TTM)
18.17%
Valuation
Price to earnings (TTM)
33.246
Price to revenue (TTM)
8.672
Price to book
4.93
Price to tangible book (TTM)
4.93
Price to free cash flow (TTM)
28.35
Free cash flow yield (TTM)
3.53%
Free cash flow per share (TTM)
1.065
Growth
Revenue change (TTM)
1,218.82%
Earnings per share change (TTM)
-141.95%
3-year revenue growth (CAGR)
217.73%
3-year earnings per share growth (CAGR)
-29.25%
What the Analysts think about STOK
Analyst ratings (Buy, Hold, Sell) for Stoke Therapeutics stock.
Bulls say / Bears say
Dosing the first patient in the global Phase 3 EMPEROR study is a significant milestone, reducing development risk and keeping Stoke’s primary program on schedule.
Second Quarter 2025 results show $355 million in cash, expected to fund operations through mid-2028 and support continued advancement toward launch readiness.
Regulatory agreement reached for the global Phase 3 EMPEROR study and the $165 million upfront from the Biogen collaboration strengthen Stoke's pathway to commercialization.
Stoke is highly dependent on its lead candidate, zorevunersen; the rest of its pipeline remains in early development, exposing the company to significant clinical trial risk if EMPEROR study results fail to meet expectations.
Commercial prospects outside North America rest largely on the partnership with Biogen, raising concentration risk if Biogen cannot deliver on ex-U.S. performance.
The EMPEROR Phase 3 pivotal data are not due until the second half of 2027, leaving Stoke in a prolonged pre-revenue phase and increasing financial risk over an extended development timeline.
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
STOK Financial Performance
Revenues and expenses
STOK Earnings Performance
Company profitability
STOK News
AllArticlesVideos
Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
Business Wire4 days ago
Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer
Business Wire1 week ago
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Business Wire4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Stoke Therapeutics stock?
Stoke Therapeutics (STOK) has a market cap of $1.7B as of October 14, 2025.
What is the P/E ratio for Stoke Therapeutics stock?
The price to earnings (P/E) ratio for Stoke Therapeutics (STOK) stock is 33.25 as of October 14, 2025.
Does Stoke Therapeutics stock pay dividends?
No, Stoke Therapeutics (STOK) stock does not pay dividends to its shareholders as of October 14, 2025.
When is the next Stoke Therapeutics dividend payment date?
Stoke Therapeutics (STOK) stock does not pay dividends to its shareholders.
What is the beta indicator for Stoke Therapeutics?
Stoke Therapeutics (STOK) has a beta rating of 1.15. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.